300233.SZ
金城医药
SZSE · Basic Materials · C 制造业 · CN
CNY 13.07
−5.08%Aug 20, 2026, 10:15 UTC
Jincheng Pharmaceutical announced its first-half 2026 results: revenue of 1.447 billion yuan, up 6.40% year-on-year, and net profit attributable to shareholders of 139 million yuan, up 220.11% year-on-year.
Source:Aug 3, 2026, 08:57 UTC
Jincheng Pharmaceutical's wholly-owned subsidiary Jincheng Taier's dydrogesterone tablets and its controlling subsidiary Jincheng Jinsu's ertapenem sodium for injection are proposed winners in the 12th national centralized drug procurement, with proposed winning prices of 25.5 yuan/box and 44.5 yuan/box respectively.
Source:Jul 24, 2026, 07:48 UTC
Jincheng Pharmaceutical's subsidiary Jincheng Taier received a drug registration certificate for injectable adenosylmethionine disuccinate from the National Medical Products Administration.
Source:Jul 10, 2026, 08:04 UTC
Jincheng Pharmaceutical's controlling shareholder Jincheng Industrial pledged 6.60 million shares to repay debt and released 9.7225 million shares from pledge.
Source: